Recombinant Human Arginase I (rhArgI) for Patients With Advanced Hepatocellular Carcinoma (HCC).
Phase of Trial: Phase I/II
Latest Information Update: 10 Feb 2015
At a glance
- Drugs BCT 100 (Primary)
- Indications Liver cancer
- Focus Pharmacodynamics; Pharmacokinetics; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 13 Mar 2012 Actual end date (February 2012) added as reported by ClinicalTrials.gov.
- 13 Mar 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.